Compare ACM Research Inc (ACMR) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACM Research Inc vs Quest Diagnostics Inc — how do they compare? ACM Research Inc trades at $98.15 (market cap $6.54B), while Quest Diagnostics Inc trades at $208.21 (market cap $23.51B). The key difference: Quest Diagnostics Inc is far larger — about 3.6× ACM Research Inc's market cap, and Quest Diagnostics Inc pays a 1.62% dividend while ACM Research Inc pays none. Which is the better fit depends on your goals.
| ACMR | DGX | |
|---|---|---|
Market Cap | $6.54B | $23.51B |
Sector | Technology | Health |
52-Week High | $126.89 | $216.02 |
52-Week Low | $23.92 | $166.42 |
Enterprise Value | $5.61B | $29.52B |
Dividend Yield | — | 1.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACMR trades at $98.52, up 0.77% today, with a bullish technical signal from moving averages and a consensus analyst price target of $110. Recent earnings showed a Q1 2026 beat but misses in prior quarters. Revenue grew to $901 million in 2025, though net income margins are under pressure. The stock has experienced volatility, with news highlighting semiconductor sector catalysts and a GF Score of 82 (GuruFocus, June 25, 2026).
Outlook is positive with 80% analyst buy ratings and semiconductor demand tailwinds, but risks include earnings inconsistency, high valuation multiples, and negative operating cash flow. Investors should weigh growth potential against execution risks in a competitive market.
Quest Diagnostics (DGX) trades at $212.38, down 1.55% today but remains near its 52-week high. The stock shows strong fundamental performance with three consecutive quarterly earnings beats and revenue growth to $11.04 billion in 2025. Technical indicators suggest a bullish trend with support at $212 and resistance at $216. Recent positive developments include New York State approval for the Haystack MRD cancer test, expanding market reach.
DGX presents a balanced investment case with solid fundamentals and analyst support, though valuation appears full. The consensus price target of $222.80 offers modest upside. Key risks include healthcare reimbursement pressures and elevated debt levels. Earnings growth and diagnostic service expansion remain primary catalysts for continued performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACM Research Inc
ACM Research develops and manufactures semiconductor process equipment, specializing in wafer cleaning and electroplating solutions. Its tools are used by global chipmakers to improve productivity and yield for logic and memory chips.
Read more on ACMR →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
